Search Within

Leora Sarah Boussi

Formats
  1. Meeting Abstract (12)
  2. Journal Article (5)
  3. Review (3)
  4. Research Letter (1)
Groups
  1. GME, Medicine (21)
  2. Graduate Medical Education (21)
  3. Hematology-Oncology Fellows (21)
  4. Weinberg Fellows (21)
  5. Center for Hematologic Malignancies (20)
  6. Department of Medicine (20)

More Groups

People
  1. Eytan Stein (15)
  2. Aaron Goldberg (6)
  3. Ioannis Kalogirou Valtis (6)
  4. Kuo-Kai Chin (6)
  5. Meira Yisraeli Salman (6)
  6. Andriy Derkach (5)

More People

Years
  1. 2025 (6)
  2. 2024 (13)
  3. 2023 (2)
Publications
  1. Blood (12)
  2. Blood Advances (2)
  3. British Journal of Haematology (2)
  4. Blood Neoplasia (1)
  5. Cancer (1)
  6. JAMA Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (14)
  2. John Wiley & Sons (2)
  3. American Medical Association (1)
  4. Cell Press (1)
  5. Elsevier Inc. (1)
  6. Rockefeller University Press (1)

More Publishers

Results (21)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs
    Journal Article

    Burton, H.; Boussi, L.; Nemirovsky, D.; Derkach, A.; Ciervo, J.; Famulare, C.; Chin, K. K.; Valtis, Y.; Yisraeli Salman, M.; Patel, K.; more...
    Cancer (2025)

    Fulltext@MSK | Save
  • Advances in menin inhibition in acute myeloid leukemia
    Review

    Boussi, L.; Cai, S. F.; Stein, E. M.
    Trends in Cancer (2025)

    Fulltext@MSK | Save
  • Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction
    Journal Article

    Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Forecasting optimal treatments in relapsed/refractory mature T- and NK-cell lymphomas: A global PETAL Consortium study
    Journal Article

    Sorial, M. N.; Han, J. X.; Koh, M. J.; Boussi, L.; Li, S.; Duan, R.; Lu, J.; Lei, M. M.; MacVicar, C. T.; Freydman, J.; more...
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Barriers to chimeric antigen receptor T-cell therapy
    Research Letter

    Valtis, Y. K.; Chin, K. K.; Nemirovsky, D.; Devlin, S. M.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from the PETAL consortium
    Journal Article

    Han, J. X.; Koh, M. J.; Boussi, L.; Sorial, M.; McCabe, S. M.; Peng, L.; Singh, S.; Eche-Ugwu, I. J.; Gabler, J.; Fernandez Turizo, M. J.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia
    Journal Article

    Chin, K. K.; Valtis, Y.; Derkach, A.; Yisraeli Salman, M.; Boussi, L.; Ciervo, J.; Geyer, M. B.; Park, J. H.; Tallman, M. S.; Glass, J. L.; more...
    Blood Neoplasia (2024)

    Fulltext@MSK | Save
  • A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available CDC-like Kinase inhibitor, BH-30236, in adults with R/R AML or HR-MDS
    Meeting Abstract

    Stein, E. M.; Boussi, L.; Mims, A.; Watts, J. M.; Mannis, G. N.; Liu, H.; Sallman, D.; Ravandi, F.; Schiller, G. J.; Wang, E. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly acute myeloid leukemia
    Meeting Abstract

    Iat, A.; Bewersdorf, J. P.; Gilhodes, J.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Bystrom, R. P.; Deangelo, D. J.; Berton, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Adult AML patients with NUP98 fusions are frequently therapy-related, and are associated with monocytic differentiation, recurring mutations in NRAS, DNMT3A and WTI and poor outcome
    Meeting Abstract

    Yao, J.; Aypar, U.; Sethi, S.; Boussi, L.; Londono, D.; Sukhadia, P.; Berman, E.; Stein, E. M.; Dogan, A.; Xiao, W.; more...
    Blood (2024)

    Fulltext@MSK | Save